Shanghai Universal Biotech's first financial report after listing! Revenue in 2021 exceeded CNY 1.1 billion

On April 24, Shanghai Universal Biotech's released its 2021 annual report. The report shows that in 2021, the company will achieve operating income of CNY 1.110 billion, a year-on-year increase of 30.69%; the net profit attributable to shareholders of listed companies will be CNY 109 million, a year-on-year increase of 42.15%; basic earnings per share will be 1.66 yuan per share, a year-on-year increase of 40.68 %.

In 2021, Shanghai Universal Biotech increased its R&D and marketing efforts and investment in RD of its own brands. The brands realized operating income of CNY 51.1618 million yuan, a year-on-year increase of 124.26%.

In addition, Shanghai Universal Biotech established a Hangzhou R&D center to develop IVD antibody research and development. The subsidiary company focuses on the development of IVD antibodies, further enhance Shanghai Universal Biotech’s RD capabilities and market competitiveness.

About Shanghai Universal Biotech: Focuses on life science research services. As the characteristics of a wide variety of life science reagents and limited variety of single-brand products, it has built a domestic professional and comprehensive one-stop life science comprehensive service platform. At present, the company provides more than 5.82 million SKUs of life science reagent products, covering different levels of research objects such as genes, proteins, cells, tissues, and animals. Business covers science basic research, medical basic research, and other industries. Shanghai Universal Biotech is one of the major suppliers with comprehensive antibody variety and specification in China.